RCE
RECCE PHARMACEUTICAL ORDINARYRecce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
RCE
RCE
RECCE PHARMACEUTICAL ORDINARY
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections.
Fundamentals
Historical Data57 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.00% | — |
| 24 Aug | — | — |
| 21 Aug | — | — |
| 20 Aug | — | — |
| 19 Aug | — | — |
| 18 Aug | — | — |
| 17 Aug | 0.00% | — |
| 14 Aug | 0.00% | — |
| 13 Aug | 0.00% | — |
Recce Pharmaceutical (RCE) Short Interest Summary
Recce Pharmaceutical (RCE) currently has 0.00% of its shares sold short (0 thousand shares, worth approximately $0K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes RCE the #686 most shorted stock on the ASX most shorted list. Short interest in RCE is down 0.00% over the past week. RCE is part of the Health Care sector on the ASX.
Recent RCE Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 17 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 14 Aug 2026 | 0.00% | 0.0M | $0.37 |
| 13 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 12 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 11 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 10 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 7 Aug 2026 | 0.00% | 0.0M | $0.38 |
| 27 July 2026 | 0.00% | 0.0M | $0.38 |
| 17 July 2026 | 0.00% | 0.0M | $0.38 |
RCE Short Selling — Frequently Asked Questions
What is Recce Pharmaceutical (RCE)'s current short interest?
Recce Pharmaceutical (RCE) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of RCE's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is RCE heavily shorted on the ASX?
RCE has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for RCE investors?
Short interest in RCE shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, RCE's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this RCE short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for RCE.